4-IPP (4-Iodo-6-phenylpyrimidine)

Cas No.:	41270-96-6
SMILES:	IC1N=CN=C(C2C=CC=CC=2)C=1
Formula:	C10H7In2
M.Wt:	282.08
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Publication:	[1]. Zheng L, et al. Macrophage migration inhibitory factor (MIF) inhibitor 4-IPP suppresses osteoclast formation and promotes osteoblast differentiation through the inhibition of the NF-κB signaling pathway. FASEB J. 2019 Jun;33(6):7667-7683.

Description:	4-IPP (4-Iodo-6-phenylpyrimidine) is a specific suicide substrate and irreversible inhibitor of macrophage migration inhibitory factor (MIF)[1].
Target:	MIF[1]
In Vivo:	4-IPP (1 mg/kg, 5 mg/kg; every 2 days; for 8 weeks) ameliorates the bone loss associated with estrogen deficiency by reducing osteoclastic activities and enhancing osteoblastic bone formation[1]. Animal Model: 8-weeks-old C57BL/6J male mice[1] Dosage: 1 mg/kg, 5 mg/kg Administration: Intraperitoneal injection; every 2 days; for 8 weeks Result: Alleviated OVX-induced osteoporosis.
In Vitro:	4-IPP is a specific suicide substrate for MIF that binds covalently and irreversibly to MIF to inhibit its biologic activity[1]. 4-IPP inhibits RANKL-induced p65 phosphorylation and nuclear translocation by preventing the interaction of MIF with thioredoxin-interacting protein-p65 complexes[1]. 4-IPP can inhibit receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis and potentiate osteoblast-mediated mineralization and bone nodule formation[1]. 4-IPP (0.5-200μM;24-72 hours) inhibits osteoclastogenesis in a dose-dependent manner[1]. 4-IPP(5-20μM; 5 days) inhibits RANKL-induced osteoclast differentiation and bone resorption [1]. Cell Cytotoxicity Assay[1] Cell Line: BMMs Concentration: 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM, 25 μM, 50 μM, 100 μM, 200 μM Incubation Time: 24 hours, 72 hours Result: Inhibited osteoclastogenesis in a dose-dependent manner. Western Blot Analysis[1] Cell Line: BMMs Concentration: 5 μM,10 μM, 20 μM Incubation Time: 1 day, 3 days, 5 days Result: Inhibited RANKL-induced osteoclast differentiation and bone resorption.
References:	[1]. Zheng L, et al. Macrophage migration inhibitory factor (MIF) inhibitor 4-IPP suppresses osteoclast formation and promotes osteoblast differentiation through the inhibition of the NF-κB signaling pathway. FASEB J. 2019 Jun;33(6):7667-7683.